// Real-Time Intelligence Feed

Financial Intelligence.
Real-Time.

SEC 8-K filings, insider trades, FDA approvals, Federal Reserve statements, and market-moving events — AI-curated, updated every 60 seconds.

14,062
Stories Indexed
Live
Feed Status
6
Data Sources
AllEarningsFDAM&AInsider TradingRegulatoryOfferingLeadershipRestructuringDividendInstitutional HoldingsBankruptcy
FDA · 14,062 results Live
FDA Amgen, Aug 23 — 0.00

FDA Approves PAVBLU — Amgen, Inc

# FDA Approves Amgen's PAVBLU, First Biosimilar Aflibercept for Retinal Disease Treatment Amgen announced FDA approval of PAVBLU (aflibercept-ayyh), the first biosimilar to Regene…

FDA ARS Aug 9 — 0.00

FDA Approves NEFFY — ARS Pharmaceuticals Operations, Inc.

# FDA Approves ARS Pharmaceuticals' NEFFY, First Nasal Epinephrine Auto-Injector Alternative ARS Pharmaceuticals Operations, Inc. received FDA approval for NEFFY (epinephrine nasa…

FDA Amneal Aug 7 — 0.00

FDA Approves CREXONT — Amneal Pharmaceuticals LLC

# FDA Approves Amneal Pharmaceuticals' CREXONT for Parkinson's Disease Treatment Amneal Pharmaceuticals LLC received FDA approval for CREXONT (carbidopa and levodopa), an oral for…

FDA Sun Jul 25 — 0.00

FDA Approves LEQSELVI — Sun Pharmaceutical Industries, Inc.

Sun Pharmaceutical Industries secured FDA approval for the oral deuruxolitinib phosphate formulation branded as LEQSELVI on July 25, 2024, reinforcing the company’s dermatology pre…

FDA Teva Jul 19 — 0.00

FDA Approves EPYSQLI — Teva Pharmaceuticals USA, Inc.

Teva Pharmaceuticals USA has secured FDA approval for EPYSQLI (eculizumab-aagh) for intravenous administration, a move expected to intensify competitive intensity in the PNH market…

FDA Teva Jun 25 — 0.00

FDA Approves PHENTERMINE AND TOPIRAMATE — Teva Pharmaceuticals, Inc.

Teva Pharmaceuticals’ June 25 approval of its generic phentermine and topiramate extended-release tablets introduces a likely price-competitive alternative to the branded Qsymia, p…

FDA UPSHER Jun 12 — 0.00

FDA Approves Unknown Drug — UPSHER SMITH LABS

# FDA Approves ANDA for Upsher Smith Labs Upsher Smith Laboratories received FDA approval for ANDA216772 on June 12, 2024, expanding its generic drug portfolio and strengthening i…

FDA Apotex Jun 11 — 0.00

FDA Approves POMALIDOMIDE — Apotex Corp.

# FDA Approves Generic Pomalidomide from Apotex Corp. Apotex Corp. has received FDA approval for its generic version of pomalidomide, an oral immunomodulatory drug used in multipl…

FDA Geron Jun 6 — 0.00

FDA Approves RYTELO — Geron Corporation

# FDA Approves Geron Corporation's RYTELO (imetelstat sodium) for Telomerase-Targeted Therapy Geron Corporation received FDA approval for RYTELO (imetelstat sodium), an intravenou…

FDA Advagen Jun 4 — 0.00

FDA Approves CARBIDOPA AND LEVODOPA — Advagen Pharma Ltd

# FDA Approves Generic Carbidopa and Levodopa from Advagen Pharma Advagen Pharma Ltd has received FDA approval for its generic formulation of carbidopa and levodopa, a standard-of…

FDA IPCA May 29 — 0.00

FDA Approves Unknown Drug — IPCA LABS LTD

# FDA Approves IPCA Laboratories' Generic Drug Application IPCA Laboratories Limited received FDA approval for an abbreviated new drug application (ANDA 209855) on May 29, 2024, e…

FDA Elite May 16 — 0.00

FDA Approves METHOTREXATE SODIUM — Elite Laboratories, Inc.

# FDA Approves Elite Laboratories' Generic Methotrexate Sodium Oral Formulation Elite Laboratories, Inc. has received FDA approval for its generic methotrexate sodium oral formula…

FDA Dr. May 8 — 0.00

FDA Approves VASOPRESSIN — Dr. Reddy's Laboratories, Inc.

Dr. Reddy's Laboratories received FDA approval for its intravenous vasopressin generic, positioning the company to immediately capture market share in the competitive hospital ther…

FDA Neurocrine Apr 30 — 0.00

FDA Approves INGREZZA SPRINKLE — Neurocrine Biosciences, Inc.

# FDA Approves Neurocrine Biosciences' INGREZZA SPRINKLE for Tardive Dyskinesia Treatment Neurocrine Biosciences, Inc. has received FDA approval for INGREZZA SPRINKLE (valbenazine…

FDA Scienture Apr 19 — 0.00

FDA Approves REZENOPY — Scienture LLC

Scienture LLC announced FDA approval for REZENOPY, a generic naloxone hydrochloride nasal spray, marking the company’s entry into the rapid-growth market for essential opioid rever…

FDA La Apr 3 — 0.00

FDA Approves ZEVTERA — La Jolla Pharmaceutical Company

La Jolla Pharmaceutical Company secured FDA approval for ZEVTERA (ceftobiprole medocaril sodium), positioning itself in the IV antibiotic market to address resistant bacterial infe…

FDA Akebia Mar 27 — 0.00

FDA Approves VAFSEO — Akebia Therapeutics, Inc.

# FDA Approves Akebia Therapeutics' VAFSEO for Anemia Treatment The FDA has approved Akebia Therapeutics' VAFSEO (vadadustat), an oral hypoxia-inducible factor (HIF) stabilizer, p…

FDA Merck Mar 26 — 0.00

FDA Approves WINREVAIR — Merck Sharp & Dohme LLC

# FDA Approves Merck's WINREVAIR (sotatercept-csrk), Expanding Treatment Options in Pulmonary Hypertension Market Merck Sharp & Dohme LLC's FDA approval of WINREVAIR (sotatercept-…

FDA Advagen Mar 5 — 0.00

FDA Approves OXCARBAZEPINE — Advagen Pharma Ltd.

Advagen Pharma Ltd. announced the March 5 FDA approval of its ANDA207717 for the oral formulation of oxycarbazepine, providing clearance to market the anticonvulsant generic. The c…

FDA Padagis Feb 22 — 0.00

FDA Approves LENALIDOMIDE — Padagis US LLC

Padagis US LLC announced the FDA approval of its oral lenalidomide ANDA, positioning the company to compete in the generic oncology market where an influx of supply is expected to …